HWAM
ADCT icon

Hennion & Walsh Asset Management’s ADC Therapeutics ADCT Stock Holding History

Hennion & Walsh Asset Management’s Portfolio ADCT Stock Details ADCT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-70,636
Closed -$317K – 839
2024
Q1 		$317K Buy
70,636
+4,700
+7% +$17.3K 0.02% 677
2023
Q4 		$109K Buy
65,936
+8,069
+14% +$7.45K 0.01% 809
2023
Q3 		$51.9K Buy
57,867
+2,298
+4% +$3.06K ﹤0.01% 796
2023
Q2 		$119K Sell
55,569
-1,497
-3% -$3.37K 0.01% 780
2023
Q1 		$111K Sell
57,066
-1,803
-3% -$6.65K 0.01% 756
2022
Q4 		$226K Buy
58,869
+7,337
+14% +$29.3K 0.01% 707
2022
Q3 		$248K Buy
51,532
+12,832
+33% +$92.9K 0.02% 664
2022
Q2 		$308K Buy
+38,700
New +$366K 0.02% 621

Other funds holding ADCT

RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
PM
Prosight Management Dallas, Texas $610M AUM 40.86% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
SCM
Silverarc Capital Management Boston, Massachusetts $980M AUM 470.8% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
PIM
Platinum Investment Management Sydney Australia 2000, Australia $397M AUM 63.96% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
AG
Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return

Hennion & Walsh Asset Management's ADCT Position: Q2 2024 in Review

Hennion & Walsh Asset Management sold out of ADC Therapeutics (ADCT) in Q2 2024, closing a stake of 70,636 shares — an estimated $317K sold.

Hennion & Walsh Asset Management first reported a position in ADCT in Q2 2022 and held it in 8 quarters. The position peaked at $317K in Q1 2024. 74 funds tracked by Wall St. Rank hold ADCT as of Q2 2024.

  • Hennion & Walsh Asset Management reported no remaining ADC Therapeutics position as of Q2 2024 after selling out during the quarter.
  • Hennion & Walsh Asset Management sold 70,636 ADC Therapeutics shares in Q2 2024, an estimated $317K.
  • Hennion & Walsh Asset Management first reported a position in ADC Therapeutics in Q2 2022 and held it in 8 quarters.
  • Hennion & Walsh Asset Management's ADC Therapeutics position peaked at $317K in Q1 2024.
  • 74 funds tracked by Wall St. Rank held ADC Therapeutics as of Q2 2024.

Based on Hennion & Walsh Asset Management's 13F filing for Q2 2024, filed 19 Jul 2024.